Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umitrelimorgene autodencel
- Development stage
- Unknown
- Lead developer
- University of Florida
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
umitrelimorgene autodencel (ITI-1000) is an autologous dendritic cell vaccine therapy designed to target the cytomegalovirus (CMV) pp65 viral antigen, which is highly expressed in glioblastoma multiforme (GBM) but absent in normal brain tissue. Developed using Immunomic Therapeutics' proprietary UNITE (UNiversal Intracellular Targeted Expression) platform, the vaccine consists of patient-derived dendritic cells electroporated with mRNA encoding the human lysosomal-associated membrane protein 1 (LAMP-1) fused to the CMV pp65 matrix protein (hLAMP:pp65). This fusion directs the antigen to the lysosomal compartment for enhanced MHC class II presentation, activating both CD4+ helper T cells and CD8+ cytotoxic T cells to mount a robust anti-tumor immune response. It is typically administered intradermally in combination with adjuvants such as GM-CSF (sargramostim) and tetanus-diphtheria (Td) toxoid preconditioning to enhance dendritic cell migration to draining lymph nodes.
- Other names
- CMV pp65-LAMP mRNA-loaded dendritic cell vaccineCMV pp65-targeted dendritic cell vaccinepp65 loaded DC vaccinepp-65 loaded DC vaccinepp 65 loaded DC vaccinepp65-DCspp-65-DCspp 65-DCs
02
Targets
Hla (Staphylococcus aureus alpha toxin)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on umitrelimorgene autodencel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umitrelimorgene autodencel.